IMV Inc is Shariah compliant. The company’s financials pass three standards and fail in two.
Ad
$81,069,380
Market cap
119.68%
Revenue Growth
BUY
Analysts' Rating
AAOIFI
S&P
DJIM
FTSE
MSCI
AAOIFI
AAOIFI ✓
| Debt ÷ Market cap (MC) | 24.24% | ✓ |
| Non-Compliant Assets ÷ MC | % |
S&P
S&P ✓
| Debt ÷ 36 mo MC | 11.7% | ✓ |
| Cash ÷ 36 mo MC | 23% | ✓ |
| AR ÷ 36 mo MC | % |
DJIM
DJIM ✓
| Debt ÷ 24 mo MC | 10.99% | ✓ |
| Cash ÷ 24 mo MC | 21.59% | ✓ |
| AR ÷ 24 mo MC | % |
FTSE
FTSE ✗
| Debt ÷ Assets | 39.21% | ✗ |
| Cash ÷ Assets | 77.05% | ✗ |
| Cash&AR ÷ Assets | 77.05% | ✗ |
MSCI
MSCI ✗
| Debt ÷ Assets | 39.21% | ✗ |
| Cash ÷ Assets | 77.05% | ✗ |
| Cash&AR ÷ Assets | 77.05% | ✗ |
Ad
Recommendation Rating
2.2
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 4.11
Low: 1.52
High: 7.99
Total Analysts: 4
Company Profile
IMV Inc. is a clinical-stage immuno-oncology company. The Company is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. It is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The Company is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Ad
Responses